Tong Zhou

Dr. Tong Zhou


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Lung Cancer
Verified
Journal Article
Closed access
HDHua-Jie Dong
Hua-Jie Dong
PLPeng Li
Peng Li
CWChang-Ling Wu
Chang-Ling Wu
XZXiao-Yue Zhou
Xiao-Yue Zhou
HLHong-Jun Lu
Hong-Jun Lu
TZTong Zhou
Tong Zhou

5 October 2024 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
CFCong Fu
Cong Fu
HGHaoran Gu
Haoran Gu
LSLin Sun
Lin Sun
ZWZhouyu Wang
Zhouyu Wang
QZQin Zhang
Qin Zhang
TZTong Zhou
Tong Zhou

31 August 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
CFCong Fu
Cong Fu
LSLin Sun
Lin Sun
XZXiaoyue Zhou
Xiaoyue Zhou
TZTong Zhou
Tong Zhou
YBYanzhi Bi
Yanzhi Bi
Mitochondrial-related nuclear genes (MNGs) have shown great importance in cancer diagnosis and prognosis, but their role in gastric cancer (GC) remains unclear. GC-related transcriptome data from the gene expression omnibus and cancer genome atlas databases were analyzed to identify differentially expressed MNGs. A prognostic risk model was constructed through univariate Cox and least absolute shrinkage and selection operator regression, validated by Kaplan–Meier (K–M) survival curve and receiver operating characteristic curve. This was followed by immune infiltration analysis, independent prognostic analysis, functional enrichment analysis, drug sensitivity analysis, drug prediction, molecular docking and construction of regulatory networks. Three prognostic genes (ATP8A2, COX15 and TARS2) were identified. The expression of TARS2 and COX15 was positively correlated with CNV, while ATP8A2 was unaffected. The risk model and nomogram, integrating risk score and clinicopathological factors, exhibited excellent predictive performance. A significant correlation was observed between prognostic genes and differential immune cells, such as T cells, B cells, and NK cells. BMS-754807, Gefitinib, JQ1, Lapatinib, and Sapitinib exhibited significant differences in sensitivity between the high-risk group and the low-risk group. The results of molecular docking showed TP8A2 has stable binding ability with cytosine, COX15 with indomethacin, and TARS2 with bisacodyl. RT-qPCR revealed downregulation of ATP8A2 and upregulation of COX15 and TARS2 in GC samples. MNGs, including ATP8A2, COX15, and TARS2, demonstrated significant associations with immune infiltration, CNV, and prognostic outcomes of GC.

24 December 2020 in Medicine
Verified
Journal Article
Open access
SWShuo Wang
Shuo Wang
XWXueqian Wang
Xueqian Wang
YZYing Zhang
Ying Zhang
TZTong Zhou
Tong Zhou
SHShuaihang Bs Hu
Shuaihang Bs Hu
WHWei Hou
Wei Hou
Background: Fluoropyrimidine combined with oxaliplatin-based chemotherapy have become the first-line treatment for advanced colorectal cancer (CRC). Chinese herbal injections (CHIs), as an important part of TCM, have been widely applied as adjunctive treatments to chemotherapy in patients with advanced CRC. However, the efficacy of this combination therapy has not been evaluated comprehensively. Methods: We will conduct this systematic review and meta-analysis in accordance with the Preferred Reported Items for Systematic Review and Meta-analysis (PRISMA) guidelines. 7 databases will be searched for related randomized controlled trials (RCTs) from their inception to August 31, 2020: PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), VIP Database for Chinese Technical Periodicals (VIP), SinoMED and Wanfang Database. Two researchers will perform study selection, data extraction, and assessment of risk of bias independently. The primary outcomes are the disease control rate (DCR) and the objective response rate (ORR), the secondary outcomes are progression-free survival (PFS), survival rate, quality of life (QoL) and adverse effects. Cochrane Review Manager (RevMan 5.3) software will be used to analyze the outcomes. Results and Conclusion: This systematic review will evaluate the efficacy of CHIs and fluoropyrimidine and oxaliplatin-based chemotherapy for advanced CRC so as to provide valuable evidence to the application of CHIs in advanced CRC. Systematic review registration: INPLASY registration number: INPLASY2020100050.

18 February 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CFCong Fu
Cong Fu
LSLin Sun
Lin Sun
CFCuncheng Feng
Cuncheng Feng
TZTong Zhou
Tong Zhou
YBYanzhi Bi
Yanzhi Bi
Background: Lung adenocarcinoma (LUAD) is a common pathological category of lung cancer. Circadian rhythm (CR) disruption has been demonstrated to impact on lung tumorigenesis in mouse models. The aim of this study was to mine genes relevant to CR in LUAD and construct a corresponding risk model.Methods: CRRGs from GSEA-MsigDB were filtered by overlapping DEGs in LUAD and NC specimens, two clusters with survival and clinical discrepancies, and CRRGs. Cox regression analysis (univariate and multivariate) was used to establish a CR-relevant risk model, which was validated in both the training and validation sets. Differences in immune infiltration, immunotherapy, and drug sensitivity between subgroups were explored. Prognostic gene expression was tested in clinical cancer and paracancer tissue samples using RT-qPCR.Results: A grand total of two prognostic genes (CDK1 and HLA-DMA) related to CR were screened. The AUC values of a CR-relevant risk model in predicting 1/3/5-years survival in LUAD patients were greater than 0.6, indicating that the efficiency of the model was decent. Then, the results of CIBERSORT demonstrated noticeable differences in the tumor microenvironment between CR-relevant high- and low-risk subgroups. In addition, the CR-relevant risk score could be performed to estimate the effectiveness of immunotherapy in LUAD patients. The sensitivity of three common drugs (homoharringtonine, lapatinib, and palbociclib) in LUAD could be evaluated by the CR-relevant risk model. Ultimately, the experimental results confirmed that the expression trends of CDK1 and HLA-DMA in our collected clinical samples were in line with the expression trends in the TCGA-LUAD dataset.Conclusion: In conclusion, a CR-relevant risk model based on CDK1 and HLA-DMA was constructed by using bioinformatics analysis, which might supply a new insight into the improved prognosis of LUAD.

4 December 2024 in Health Science Reports
Verified
Journal Article
Open access
WYWei Ye
Wei Ye
LSLin Sun
Lin Sun
CFCong Fu
Cong Fu
HDHuajie Dong
Huajie Dong
TZTong Zhou
Tong Zhou
Background and Aims: The biological function of lysosomes has been increasingly appreciated in cancer. However, the relationship between lysosome and lung adenocarcinoma (LUAD) was not well understood. In this study, a lysosome‐related signature was developed for LUAD risk stratification and prognosis prediction.Methods: Download RNA‐seq data of LUAD and clinical information of corresponding samples from the UCSC‐Xena platform. GSE31210 databases is used as a validation cohort. The lysosome‐related genes was obtained from molecular signature database. The differentially expressed genes (DEGs) as well as lysosome‐associated prognosis signatures were identified by using univariate, multivariate cox, and Lasso regression. A nomogram was constructed and evaluated using ROC and DCA.Results: A total of 109 lysosome‐related DEGs were identified and 30 prognostic related DEGs were subsequently screened. Cluster analysis further divides the TCGA cohort into clusters 1 and 2. Patients in cluster 2 had a worse prognosis (p = 0.016), lower LYSOSOME score. Enrichment analysis showed that 21 significantly enriched gene sets in the cluster 2 were activated. And 10 pathways, such as E2F_TARGETS, G2M_CHECKPOINT were upregulated. Multivariate Cox regression analysis identified 17 best prognostic genes as risk signature. An independent prognostic factor, the risk signature, was identified. A prognostic nomogram including risk signature, age, TNM stage, and gender was constructed, and ROC and DCA curves proved its excellent performance. We examined CTSZ and AP3S2 protein expression in 48 stage 3–4 NSCLC samples. Low AP3S2 expression was associated with better prognosis (median overall survival: 37.87 vs. 8.53 months, p = 0.0211). Increased CTSZ expression also indicated better prognosis (median overall survival: 6.77 vs. 30.50 months, p = 0.0306).Conclusion: We identified molecular subtypes and lysosomal‐based prognostic signatures for LUAD patients, as well as 17 genes that serve as a biomarker for evaluating the prognosis of LUAD patients.